Zydus Lifesciences has received the EIR report from the USFDA for the inspection conducted at its API manufacturing facility located at Dabhasa near Vadodara. This facility underwent an inspection from 21st to 25th April 2025 and has been classified as Voluntary Action Indicated (VAI). FDA confirmed the inspection as closed.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
